VRDN vs. CDNA, CSTL, FLGT, SERA, OPGN, PMD, VCYT, FTRE, GH, and ZNTL
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Sera Prognostics (SERA), OpGen (OPGN), Psychemedics (PMD), Veracyte (VCYT), Fortrea (FTRE), Guardant Health (GH), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "medical" sector.
CareDx (NASDAQ:CDNA) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
CareDx has higher revenue and earnings than Viridian Therapeutics. CareDx is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
CareDx has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
In the previous week, CareDx had 6 more articles in the media than Viridian Therapeutics. MarketBeat recorded 10 mentions for CareDx and 4 mentions for Viridian Therapeutics. CareDx's average media sentiment score of 1.02 beat Viridian Therapeutics' score of 0.58 indicating that Viridian Therapeutics is being referred to more favorably in the news media.
CareDx presently has a consensus target price of $16.50, indicating a potential upside of 4.43%. Viridian Therapeutics has a consensus target price of $34.60, indicating a potential upside of 183.14%. Given CareDx's stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than CareDx.
CareDx has a net margin of -66.59% compared to CareDx's net margin of -75,737.85%. Viridian Therapeutics' return on equity of -55.08% beat CareDx's return on equity.
CareDx received 380 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 72.06% of users gave Viridian Therapeutics an outperform vote while only 66.72% of users gave CareDx an outperform vote.
Summary
CareDx beats Viridian Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
